About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
minkabu the infonoid
(C) 2024 MINKABU THE INFONOID, Inc.
kabutan

Daito Pharmaceutical Co.,Ltd.(4577) Summary

4577
TSE Prime
Daito Pharmaceutical Co.,Ltd.
2,077
JPY
-4
(-0.19%)
May 1, 9:30 am JST
14.53
USD
Apr 30, 8:30 pm EDT
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
20.9
PBR
0.61
Yield
3.37%
Margin Trading Ratio
57.10
Stock Price
May 1, 2025
Opening May 1, 9:00 am
2,071 JPY 14.48 USD
Previous Close Apr 30
2,081 JPY 14.59 USD
High May 1, 9:30 am
2,077 JPY 14.53 USD
Low May 1, 9:00 am
2,071 JPY 14.48 USD
Volume
500
Trading Value
1.00M JPY 7.28K USD
VWAP
2073.0 JPY 14.56 USD
Minimum Trading Value
207,700 JPY 1,453 USD
Market Cap
0.03T JPY 0.22B USD
Number of Trades
3
Liquidity & Number of Trades
As of May 1, 2025
Liquidity
Mid
1-Year Average
198
1-Year High Jul 16, 2024
874
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 25, 2025 2,700 14,300 5.30
Apr 18, 2025 4,100 12,300 3.00
Apr 11, 2025 3,100 15,100 4.87
Apr 4, 2025 3,000 19,400 6.47
Mar 28, 2025 3,300 15,800 4.79
Company Profile
Daito Pharmaceutical Co., Ltd. specializes in the manufacturing of active pharmaceutical ingredients (APIs) and contract manufacturing of pharmaceutical products, primarily serving generic drug manufacturers.
Sector
Pharmaceuticals
Daito Pharmaceutical Co., Ltd. focuses on the manufacturing and sales of APIs and pharmaceutical products, as well as contract manufacturing and distribution, while also engaging in health food sales. In the API sector, the company manufactures and sells both in-house developed products and those co-developed with partners, maintaining extensive business relationships with domestic and international pharmaceutical companies. The company has a particularly strong track record in supplying APIs, mainly self-developed, to generic drug manufacturers. In pharmaceutical production, Daito actively engages in contract manufacturing of brand-name drugs for major domestic pharmaceutical companies, while also developing and manufacturing generic drugs. With its high-quality control capabilities and production facilities capable of handling various dosage forms, the company is able to undertake manufacturing contracts from major innovative drug companies. Daito's integrated manufacturing system, covering everything from APIs to finished pharmaceutical products, serves as a significant competitive advantage.